To further demonstrate the therapeutic efficacy of W2014-S, subcutaneous mouse xenografts of NSCLC cell line (A549) and lung cancer patient-derived xenograft (PDX) model harboring aberrantly active STAT3 were utilized to evaluate the anti-tumor effect. This evidence concerns the gene STAT3 and neoplasm.